Lactobacillus Paracasei L-30 for Bone Regeneration With Fewer Side Effects

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current osteoporosis treatments, such as bisphosphonates, cause significant side effects and require long-term drug administration, necessitating the development of natural materials with minimal toxicity and side effects for effective prevention and treatment.

Innovation Solution

A novel Lactobacillus paracasei L-30 strain with bone regeneration efficacy, promoting osteoblast differentiation and inhibiting osteoclast formation, is used in pharmaceutical and food compositions to enhance bone density and prevent bone diseases.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Strength

If bisphosphonates are used to treat osteoporosis, then bone density is improved, but serious side effects occur due to inhibition of osteoclasts

Engineering Contradiction:

Improvebone densityVSAvoidside effects

Core Design Contradiction:

StrengthVSObject-affected harmful factors

Solution Approach 1:

The patent introduces Lactobacillus paracasei L-30 as a biological intermediary that mediates bone metabolism through probiotic mechanisms rather than direct osteoclast inhibition. This probiotic strain acts as a mediator that promotes osteoblast differentiation and bone formation through safe biological pathways, avoiding the harmful side effects of conventional bisphosphonate therapy while still achieving bone density improvement

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention changes the therapeutic parameter from chemical inhibition of osteoclasts to biological promotion of osteoblasts. By using Lactobacillus paracasei L-30, the treatment mechanism shifts from suppressing bone resorption to actively promoting bone formation, fundamentally changing the therapeutic approach to avoid side effects while maintaining efficacy

Inventive Principle:

Principle #35Parameter changes

2Reliability

If long-term drug treatment is administered for osteoporosis, then disease management is maintained, but treatment complexity and duration increase

Engineering Contradiction:

Improvedisease managementVSAvoidtreatment duration

Core Design Contradiction:

ReliabilityVSDuration of action of moving object

Solution Approach 1:

The Lactobacillus paracasei L-30 probiotic strain establishes itself in the gastrointestinal tract and continuously produces bone-regulating substances through metabolic activity. This self-service mechanism allows the probiotic to maintain therapeutic effects through its own biological functions rather than requiring external drug administration, enabling long-term disease management without continuous medical intervention

Inventive Principle:

Principle #25Self-service

Solution Approach 2:

The probiotic strain is administered in advance to establish colonization and begin producing bone-regulating substances before significant bone loss occurs. This preliminary action allows the body to build up protective effects over time, reducing the need for intensive long-term treatment and enabling preventive management of osteoporosis

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentEP4728882A1Lactobacillus paracasei l-30 strain and uses thereof

Publication Date: 2026.04.22 NEOREGEN BIOTECH

Figure 1
Figure 2
Figure 3~4

AI summary

The present invention relates to a novel Lactobacillus paracasei L-30 and uses thereof. More specifically, the present invention is directed to Lactobacillus paracasei L-30 (KCTC16035BP), which has ability to promote osteoblast differentiation or formation, inhibiting osteoclast differentiation or formation, and enhancing immune activity, thereby enabling bone regeneration, and to a pharmaceutical composition including the same for the treatment or prevention of bone diseases.